Akt is constitutively activated in up to 70% of human melanomas and has an important role in the pathogenesis of the disease. However, little is known about protein phosphatases that dephosphorylate and thereby inactivate it in melanoma cells. Here we report that suppression of pleckstrin homology domain and leucine-rich repeat Ser/Thr protein phosphatase 1 (PHLPP1) by DNA methylation promotes Akt activation and has an oncogenic role in melanoma. While it is commonly downregulated, overexpression of PHLPP1 reduces Akt activation and inhibits melanoma cell proliferation in vitro, and retards melanoma growth in a xenograft model. In contrast, knockdown of PHLPP1 increases Akt activation, enhances melanoma cell and melanocyte proliferation, and results in anchorage-independent growth of melanocytes. Suppression of PHLPP1 involves blockade of binding of the transcription factor Sp1 to the PHLPP1 promoter. Collectively, these results suggest that suppression of PHLPP1 by DNA methylation contributes to melanoma development and progression.
INTRODUCTION
Aberrant activation of survival signaling pathways causes uncontrolled proliferation and resistance to apoptosis, and has an important role in cancer development, progression and resistance to treatment. 1, 2 In melanoma, activation of the mitogen-activated protein kinase (MAPK) pathway stems primarily from activating mutations of BRAF. 3, 4 Targeting mutant BRAF has achieved unprecedented responses in the treatment of metastatic melanoma patients. [5] [6] [7] However, primary and acquired resistance, which is commonly associated with activation of other survival pathways, particularly, the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, remains a major obstacle in the quest for curative treatment. [8] [9] [10] [11] Indeed, activation of PI3K/Akt signaling has been shown to cooperate with mutant BRAF in melanomagenesis using in vivo models. 12, 13 PI3K signaling is initiated with engagement of extracellular growth factors to receptor tyrosine kinases. This results in recruitment of PI3K to plasma membrane-anchored receptors where it is activated leading to increases in the production of phosphatidylinositol (3, 4) bisphosphate (PI(3,4)P 2 ) and phosphatidylinositol (3, 4, 5) trisphosphate (PI(3,4,5)P 3 ), which in turn bind to and activate multiple downstream effectors. [14] [15] [16] Among them is Akt that is activated by sequential phosphorylation at its activation loop (Thr308) and hydrophobic motif (Ser473). 17, 18 Of note, while phosphorylation at Thr308 partially activates Akt, its full activation requires phosphorylation at Ser473. [19] [20] [21] Although upstream mechanisms regulating Akt activation are being increasingly uncovered, less is known about protein phosphatases that dephosphorylate and thus inactivate it in melanoma. Nevertheless, recent studies have shown that pleckstrin homology (PH) domain and leucine-rich repeat Ser/Thr protein phosphatase (PHLPP) proteins, a family of hydrophobic motif phosphatases of AGC protein kinases, dephosphorylate Akt at Ser473 in various types of cancer cells, including those of colon and prostate cancer, pancreatic cancer, leukemia and glioblastoma. 20, [22] [23] [24] [25] [26] [27] [28] Indeed, PHLPP1 and/or PHLPP2 are commonly reduced and have a tumor-suppressive role in these malignancies. 20, [22] [23] [24] [25] [26] [27] [28] The PHLPP phosphatase family comprises three isozymes, the alternatively spliced PHLPP1a and PHLPP1b, and PHLPP2, a separate gene product. 20, 22, 24 PHLPP1a differs from PHLPP1b only in the first exon, leading to an N-terminal extension. 20, 22, 24 Both PHLPP1 and PHLPP2 serve as the hydrophobic motif phosphatases for Akt, PKC and ribosome protein S6 kinase 1 (S6K1). 20, 22, 24, 29, 30 In addition, they dephosphorylate and thus activate the proapoptotic protein kinase Mst1. 20, 22, 31 However, substrate specificity exists among the isozymes. In particular, while PHLPP1 dephosphorylates Akt2 and Akt3 but not Akt1, PHLPP2 dephosphorylates Akt1 and Akt3 but not Akt2. 20, 22, 25, 32 PHLPP has also been shown to negatively regulate ERK activation, although its direct target in this context is unknown. 20, 24, 33 The PI3K/Akt pathway is constitutively activated in up to 70% of melanomas. 4, 34 This is frequently associated with downregulation of phosphate and tensin homolog deleted on chromosome 10 (PTEN) and/or phosphatidylinositol 4,5-bisphosphate 5-phosphatase (PIB5PA) mediated by genetic or epigenetic mechanisms, and, in some cases, related to activating mutations in NRAS, PI3KCA (the gene encoding the p110a catalytic subunit of PI3K) and genes of receptor tyrosine kinases such as c-KIT. 4, [35] [36] [37] In this report, we provide evidence that the reduced expression of PHLPP1 also contributes to elevated activation of PI3K/Akt signaling, and has an oncogenic role in melanoma. Moreover, we show that PHLPP1 DNA methylation has an important role in suppression of PHLPP1 in melanoma cells.
RESULTS

PHLPP1 is downregulated in human melanoma
We examined the expression of PHLPP1 in a panel of melanoma cell lines by western blotting using an antibody directed to both PHLPP1a and PHLPP1b. These melanoma cell lines had varying status of the most common mutations in BRAF (BRAF V600E ) and NRAS (NRAS Q61R ) but harbored no mutations in other key components of the PI3K/Akt pathway, including PI3KCA, EGFR, c-KIT and PTEN. 37 The results showed that the PHLPP1 protein was expressed exclusively as the PHLPP1b isoenzyme in melanocytes and melanoma cells (for simplicity, the term PHLPP1 will be used hereafter to refer to the protein), and that the expression of PHLPP1 was commonly lost or reduced in melanoma cell lines compared with pooled melanocytes of three different lines (HEMa-LP, HEMa-DP and HEMn-LP) (pooled melanocytes were used to simplify analysis, as these normal melanocyte lines expressed similarly higher levels of PHLPP1 than melanoma cell lines; Figure 1a and Supplementary Figure S1 ). In contrast to PHLPP1, no reduction in PHLPP2 was found in melanoma cells compared with melanocytes ( Figure 1a ). Of note, there was no correlation between PHLPP1 or PHLPP2 levels and activation of Akt as Figure 1 . PHLPP1 is downregulated in melanoma cells. (a) Whole-cell lysates from pooled melanocytes of three different lines (HEMa-LP, HEMa-DP and HEMn-LP) and indicated melanoma cell lines were subjected to western blot analysis. Data shown are representative of three individual experiments. (b) Total RNA from pooled melanocytes of three different lines (HEMa-LP, HEMa-DP and HEMn-LP) and indicated melanoma cell lines were subjected to qRT-PCR analysis of PHLPP1 mRNA expression. The relative abundance of PHLPP1 mRNA expression in melanocytes were arbitrarily designated as 1 (n ¼ 3, mean ± s.e.m.). (c) Representative microphotographs of immunohistochemistry staining of PHLPP1 on melanocytic tumor tissue sections. Scale bar, 100 mm. The PHLPP1 antibody specificity was confirmed by using blocking peptides that abolished the immunoreactivity in IHC assays. (d) Quantitation of PHLPP1 expression levels in melanocytic tumors (Supplementary Tables  S1 and S2 ). Data shown are mean immunoreactive scores (IRSs) ± s.e.m. Student's t-test, *Po0.01. (e) Total RNA from pooled melanocytes of three different lines (HEMa-LP, HEMa-DP and HEMn-LP) and indicated fresh melanoma isolates were subjected to qRT-PCR analysis of PHLPP1 mRNA expression. The relative abundance of PHLPP1 mRNA expression in melanocytes were arbitrarily designated as 1 (n ¼ 3, mean ± s.e.m.). (f ) Whole-cell lysates from pooled melanocytes of three different lines (HEMa-LP, HEMa-DP and HEMn-LP) and representative fresh melanoma isolates sampled those as shown in e were subjected to western blot analysis of PHLPP1 and GAPDH (as a loading control).
determined by the expression of pSer473-Akt among the melanoma cell lines (Supplementary Figure S2) . qPCR analysis using primers directed to both PHLPP1a and PHLPP1b showed that PHLPP1 mRNA levels were also reduced in melanoma cells (Figure 1b) , whereas there was no significant difference in PHLPP2 mRNA levels between melanoma cells and melanocytes (Supplementary Figure S3) .
We also examined the expression of PHLPP1 in relation to melanoma development and progression by use of immunohistochemistry in tissue microarrays (TMAs) constructed from 100 formalin-fixed paraffin-embedded melanocytic tumors. The same cohort of TMAs had been used previously for analysis of the expression of PTEN, PIB5PA and pSer473-Akt. 37 The results revealed that PHLPP1 expression was frequently reduced in melanomas compared with nevi, with complete loss in 3 of 40 metastatic and 1 of 40 primary melanomas (Figures 1c and d and Supplementary  Table S1 ). However, there was no significant difference in PHLPP1 levels between thin and thick primary melanomas, or between primary and metastatic melanomas (Figures 1c and d and Supplementary Table S1 ). Similar to studies in cell lines, there was no overall correlation between PHLPP1 levels and activation of Akt in melanocytic tumor sections nor was there a significant relationship between the expression of PHLPP1 and PTEN or PIB5PA (Supplementary Table S2 ). 37 Reduction in PHLPP1 expression was also evidenced by examination of a panel of fresh melanoma isolates from a different cohort of patients by qPCR and western blot analysis (Figures 1e and f) . Collectively, these results indicate that PHLPP1 is commonly suppressed in melanoma cells.
PHLPP1 downregulates Akt activation and inhibits proliferation and survival of melanoma cells
We focused on examination of the functional significance of PHLPP1 downregulation in melanoma cells by introducing a PHLPP1 construct with lentiviral transduction into MM200 and Mel-RM cells (Figure 2a) . Overexpression of PHLPP1 inhibited cell growth as shown in clonogenic assays (Figure 2b ), which was related to induction of apoptosis, albeit moderately (o20% apoptotic cells) (Figure 2c and d) , and inhibition of cell proliferation (Figure 2e ). This was associated with downregulation of pSer473-Akt (Figure 2a) . Similarly, phosphorylation of PKCbII (pSer660-PKCbII) was also reduced (Figure 2a) . In contrast, overexpression of PHLPP1 only displayed a moderate inhibitory effect on activation of ERK1/2 (Figure 2a) . Noticeably, p27 and p21, two major negative regulators of cell cycle progression that can be inhibited directly or indirectly by Akt signaling, 38 was increased in MM200 and Mel-RM cells overexpressing PHLPP1 (Figure 2a) . Moreover, phosphorylation of GSK3b, another downstream target of Akt, was decreased when PHLPP1 was overexpressed (Figure 2a) .
To facilitate further investigation, we established stable PHLPP1-overexpressing MM200 and Mel-RM sub-lines (MM200.PHLPP1 and Mel-RM.PHLPP1). These sub-lines displayed reduced pSer473-Akt and decelerated cell proliferation (Figure 3a and Supplementary Figure S4) . Similarly, pSer660-PKCbII was decreased, whereas the native form of PKCbII was also reduced, albeit moderately, consistent with negative regulation of PKC levels by PHLPP. 29 Introduction of a phosphomimetic mutant Akt construct (Akt/S473D) that cannot be dephosphorylated by PHLPP into MM200.PHLPP1 and Mel-RM.PHLPP1 cells restored their proliferation potential, which was associated with downregulation of p21 and p27 (reversal of PHLPP1-mediated upregulation of the proteins) (Figures 3b-d) . 26 In contrast, introduction of a phosphomimetic mutant PKC (PKC/ S660E) that cannot be dephosphorylated by PHLPP did not impinge on the reduced proliferation potential of MM200.PHLPP1 and Mel-RM.PHLPP1 cells (Figures 3b-d ). These results point to an essential role of dephosphorylation of Akt in PHLPP1-mediated inhibition of melanoma cell proliferation. In support, small interference RNA (siRNA) knockdown of PHLPP1 in ME4405 cells that expressed relatively high levels of PHLPP1 accelerated, albeit moderately, cell proliferation, which was associated with elevated activation of Akt and was abolished by the addition of the PI3K inhibitor LY294002 (Figures 3e-g ). Deregulation of PHLPP1 modulates melanoma tumor growth To investigate whether PHLPP1-mediated inhibition of Akt has a role in suppression of melanocyte transformation, we knocked down PHLPP1 in human adult epidermal melanocytes (HEMa-LP cells) with retroviral transduction of PHLPP1 short hairpin RNA (shRNA) (Figure 4a ). This caused anchorage-independent growth and increased proliferation of the cells (Figures 4b and c) . The effect of knockdown of PHLPP1 on melanocyte proliferation could be reversed by the addition of LY294002, indicating that it was mediated by activation of PI3K/Akt signaling (Figure 4d ).
We exploited tumor growth of MM200.PHLPP1 and Mel-RM.PHLPP1 cells and their corresponding control cells carrying vector alone subcutaneously transplanted into nu/nu mice to determine the functional significance of expression of PHLPP1 in melanoma growth in vivo. In this model, overexpression of PHLPP1 caused significant retardation of tumor growth (Figures 4e-g ). This was associated with suppression of activation of Akt and upregulation of p27 (Figure 4h ). The role of inhibition of PI3K/ Akt signaling in PHLPP1-mediated suppression of melanoma tumor growth was confirmed by transplanting MM200.PHLPP1 and 4i and h). Although it is known that overexpression of wildtype Akt promotes melanoma growth in vivo, 39 it is conceivable that melanoma tumor growth might not be markedly rescued should MM200.PHLPP1 co-introduced with wild-type Akt be transplanted into nu/nu mice, as high levels of PHLPP1 would deactivate Akt and inhibit its promoting effect on melanoma growth.
PHLPP1 DNA methylation has an important role in suppression of its expression Although PHLPP1 was reduced at the mRNA level, the turnover rate of its transcript in melanoma cells was similar to that in melanocytes as shown by actinomycin D-chase assays (Figure 5a ), indicating that downregulation of PHLPP1 mRNA was due to either genomic alterations or transcriptional decreases. Analysis of a previously published data set of 76 melanoma cell lines assessed with 317K whole-genome SNP arrays revealed that PHLPP1 gene copy number reduction and loss of heterozygosity (LOH) are rare. 40 Consistently, we did not find PHLPP1 copy number reduction in a panel of melanoma cell lines and fresh melanoma isolates compared with melanocyte lines by qPCR analysis of genomic DNA (Figure 5b ).
PHLPP1 is suppressed by DNA hypermethylation or histone hypoacetylation in other types of cells. 27, 41 We examined whether similar mechanisms are involved in downregulation of PHLPP1 in melanoma cells. While the methylation inhibitor 5-aza-2 0 -deoxycytidine (5-aza) triggered increases in PHLPP1 (Figures 5c  and d) , the HDAC inhibitor SAHA did not alter the expression of PHLPP1 (Supplementary Figure S5) . PTEN and PIB5PA that are known to be upregulated, respectively, by 5-aza and SAHA in melanoma cells were included as controls (Figures 5c and d and Supplementary Figure S5) . These results suggest that PHLPP1 is epigenetically suppressed by its DNA hypemethylation in melanoma cells. Indeed, methylation-specific PCR analysis showed that PHLPP1 DNA is commonly hypermethylated in melanoma cell lines but not in melanocytes (Figure 5e ). Similarly, PHLPP1 DNA hypermethylation was also detected in four of five fresh melanoma isolates, suggesting that epigenetic suppression of PHLPP1 by DNA methylation is also common in melanoma cells in vivo (Supplementary Figure S6) .
Notably, 5-aza also induced a decrease in Akt activation that was mediated at least in part by increased PHLPP1, in that knockdown of PHLPP1 attenuated the effect of 5-aza on pSer473-Akt (Figures  5f-h ). The functional consequence of 5-aza-triggered upregulation of PHLPP1 was further demonstrated by inhibition of 5-azainduced reduction in cell proliferation with knockdown of PHLPP1 (Figures 5f and i) , which recapitulated, at least in part, the effect of introduction of Akt/S473D into the cells (Figures 3b and c) .
Suppression of PHLPP1 transcription by DNA methylation involves inhibition of Sp1 binding to the PHLPP1 promoter To further examine the mechanisms involved in regulation of PHLPP1, a series of CpG-free luciferase reporters (pCpGL-) containing incrementally deleted sequences in the À 804/ þ 90 region (numbers relative to the transcription start site) were constructed and transiently transfected into MM200 and Mel-RM cells (Figure 6a) . 42, 43 Transcriptional activity was detected with all the constructs but pCpGL-PHLPP1-( À 3/ þ 90) (Figure 6b ). The shortest fragment that was transcriptionally active was pCpGL-PHLPP1-( À 64/ þ 90) (Figure 6b) . Therefore, the region between À 64 and À 3 is involved in transcriptional activation of PHLPP1 when its DNA methylation is absent.
The À 64/ À 3 region of the PHLPP1 promoter contains a consensus binding site for the transcription factor Sp1 (Supplementary Figure S7) . Deletion of the Sp1-binding site reduced transcriptional activity of pCpGL-PHLPP1-( À 64/ þ 90) (Figure 6c ), suggesting that Sp1 has an important role in activating PHLPP1 transcription when it is not methylated. In support, 5-aza markedly enhanced binding of endogenous Sp1 to the À 64/ À 3 region of the PHLPP1 promoter (Figure 6d) . Moreover, siRNA knockdown of Sp1 inhibited upregulation of PHLPP1 in response to 5-aza (Figures 6e and f) .
DISCUSSION
In this report, we present evidence that suppression of the Ser/Thr protein phosphatase PHLPP1 by DNA methylation has an oncogenic role by promoting activation of Akt in melanoma. While its expression was commonly reduced or lost in melanoma cells in vitro and in vivo, introduction of exogenous PHLPP1 caused reduction in activation of Akt, which led to inhibition of proliferation and survival of melanoma cells in vitro, and retardation in melanoma tumor growth in a xenograft mouse model. In contrast, knockdown of PHLPP1 increased Akt activation, enhanced melanoma cell and melanocyte proliferation, and resulted in anchorage-independent growth of melanocytes. Our results also reveal that inhibition of binding of the transcription factor Sp1 to the PHLPP1 gene promoter contributes to DNA methylation-mediated suppression of PHLPP1 in melanoma cells.
Activation of Akt involves sequential phosphorylation on its activation loop (Thr308) and hydrophobic motif (Ser473). 17, 18 However, Akt phosphorylated at Thr308 alone is only B10% as active as the fully phosphorylated form and only retains activity toward a limited group of substrates, whereas phosphorylation of Ser473 allows for full activation and phosphorylation of all its substrates. [19] [20] [21] Therefore, the balance between phosphorylation and dephosphorylation of Akt at Ser473 is critical for regulation of Akt activity. 20, 24 Indeed, we found that introduction of exogenous PHLPP1, a hydrophobic motif phosphatase, inhibited, whereas knockdown of PHLPP1 enhanced, Akt activation, indicating that PHLPP1 has an important role in controlling activation of Akt, and that reduced expression of PHLPP1 contributes to constitutive activation of Akt signaling in melanoma cells. In line with this, PHLPP1 and/or PHLPP2 are often expressed at reduced levels and, upon overexpression, suppress Akt activation in a number of other malignant tumors. [23] [24] [25] [26] [27] [28] As aberrant activation of Akt in melanoma is commonly associated with reduced expression of PTEN, 4, [35] [36] [37] it is conceivable that reduction in PHLPP1 and PTEN may cooperate in promoting Akt activation in melanoma cells as they do in glioblastoma and prostate cancer cells. 28, 44 In addition, PHLPP1 deficiency may also cooperate with loss of PIB5PA that is also common in melanoma to promote Akt activation. 37 Of note, inositol polyphosphate-4-phosphatase type II (INPP4B) that can negatively regulate PI3K signaling by dephosphorylating the 4-position of PI(3,4)P 2 is also frequently lost in a number of cancers including melanoma due to LOH at its locus. 45, 46 However, whether loss of this lipid phosphatase contributes to enhanced PI3K signaling in melanoma remains to be defined. Similarly, whether loss of INPP4B cooperates with downregulation of PTEN, PIB5PA and/or PHLPP1 to promote activation of Akt needs to be investigated.
As anticipated, overexpression of PHLPP1 reduced phosphorylation of PKC, which, like Akt, belongs to the AGC kinase family, in melanoma cells. 20, 29 Moreover, it downregulated activation of ERK1/2, albeit moderately. Inhibition of ERK activation by PHLPP1 has been previously observed in other cell types, but the direct target(s) has not been identified. 20, 29, 33 Whether PHLPP1 similarly inhibits phosphorylation of ribosome protein S6 kinase 1 (S6K1) and Mst1 in melanoma cells as it does in other types of cells remains unknown, 20, 22, 30, 31 but low levels of apoptosis triggered by PHLPP1 overexpression argues against phosphorylation of Mst1 as a major biological effect of PHLPP1 on melanoma cells. 20, 31 Regardless, inhibition of melanoma cell proliferation appeared to be primarily mediated by its inhibitory effect on Akt. This was demonstrated by reversal of PHLPP1-mediated inhibition of melanoma cell proliferation with a PHLPP1-resistant form of Akt, whereas inhibition of PI3K reversed the increase in melanoma cell proliferation resulting from PHLPP1 knockdown. In addition, inhibition of PI3K similarly abolished the increase in melanocyte proliferation caused by knockdown of PHLPP1, consolidating that the oncogenic role of PHLPP1 deficiency in melanocytic cells is largely due to its promoting effect on activation of Akt.
Intriguingly, PHLPP2 that can also dephosphorylate Akt leading to its inactivation did not appear to be suppressed in melanoma cells. While PHLPP1 and PHLPP2 selectively bind to and regulate Akt2 and Akt1, respectively, they can both bind to and dephosphorylate Akt3, 20, 22, 25, 32 which is the major isoform of Akt in melanoma cells. 47 It seems likely that there had been no selective pressure for melanoma cells to accumulate redundant dephosphorylating mechanisms toward Akt3. On the other hand, the presence of PHLPP2 may act as a negative feedback mechanism to circumvent superactivation of Akt that triggers senescence of melanoma cells. 45 Indeed, inhibition of GSK3b by Akt causes stabilization of PHLPP1 via blockade of its interaction with the E3 ligase b-TrCP, 20, 48 but if PHLPP2 is subjected to regulation by similar mechanisms remains unknown.
PHLPP1 was reduced at the mRNA level, but the turnover rate of its mRNA in melanoma cells was similar to that in melanocytes. This indicates that downregulation of PHLPP1 mRNA is primarily due to either genomic alterations or transcriptional decreases. The PHLPP1 gene is located at chromosome 18q21.33, which frequently undergoes LOH in colon cancer. 22, 24 However, LOH of the PHLPP1 gene in melanoma is rare. 40 Similarly, our results, along with others', indicate that PHLPP1 copy number reduction is uncommon in melanoma. 40 Therefore, similar to the upstream negative regulators of PI3K/Akt signaling, PTEN and PIB5PA, PHLPP1 may be suppressed by epigenetic mechanisms in melanoma. 37, 49 Indeed, we identified PHLPP1 DNA methylation as a common mechanism for downregulation of PHLPP1 in melanoma. This reinforces the importance of epigenetic suppression in controlling the expression of negative regulators of the PI3K/Akt pathway, and indicates that inhibition of DNA methylation can reduce Akt activation through upregulation of PHLPP1 along with PTEN that is also commonly inhibited by DNA methylation in melanoma cells. 37 , 49 Although we did not observe any effect of the histone deacetylase inhibitor SAHA on PHLPP1 expression, it has been recently reported that inhibition of HDAC3 increases PHLPP1 expression and supresses Akt signaling in chondrocytes. 41 Moreover, microRNA-190 has been shown to target PHLPP and thus contribute to arsenic-induced carcinogenesis in beas-2B human bronchial epithelial cells. 50 It appears therefore that PHLPP1 is regulated by various epigenetic mechanisms in a cell type-dependent manner.
Although our results did not define the exact fragment(s) at which DNA methylation is responsible for suppression of PHLPP1, it is known that loss of PHLPP1 protein expression in chronic lymphocytic leukemia cells is closely correlated with a high degree of PHLPP1 DNA methylation at the end of exon 1, whereas little methylation was observed in the promoter region. 27 Nevertheless, transcriptional repression of gene expression by DNA methylation involves inhibition of access of transcription factors to the active region of gene promoters. 42, 43 Consistently, we found that DNA methylation inhibited binding of the transcription factor Sp1 to a region of the PHLPP1 promoter that was active when DNA methylation was absent. Moreover, inhibition of the association between Sp1 and the fragment blocked upregulation of PHLPP1 in response to 5-aza. These data identify Sp1 as an important transcription factor that activates PHLPP1 transcription, should PHLPP1 DNA methylation be removed. Of interest, Sp1 is upregulated in a number of malignant tumors and has an important role in suppression of PIB5PA expression by histone hypoacetylation in melanoma. 37, 51 Therefore, Sp1 has multiple effects on Akt activation depending on the PHLPP1 DNA methylation and histone acetylation status. The transcription factors SMAD3 and nuclear transcription factor Y (NFY) have been implicated in regulation of PHLPP expression, 52, 53 but whether their transcriptional activity toward PHLPP1 is similarly regulated by DNA methylation needs to be further investigated.
The role of PHLPP1 deficiency in the pathogenesis of melanoma is echoed by its reduced expression in melanoma cells in vivo. The significant decrease in PHLPP1 levels in primary melanomas compared with nevi suggests that downregulation of PHLPP1, similar to reduction in PTEN and PIB5PA, is an early event during melanomagenesis. 37, 47, 54 This was supported by the finding that knockdown of PHLPP1 resulted in anchorage-independent growth of melanocytes. However, there was no overall correlation between the levels of PHLPP1 expression and Akt activation, reiterating that PI3K/Akt signaling is regulated by multiple mechanisms.
1,2 As PIB5PA and PTEN were also commonly reduced or lost in melanoma, 4, 37 it is possible that downregulation of PHLPP1 and reduction of PTEN and/or PIB5PA may cooperatively promote activation of PI3K/Akt signaling in vivo, and that melanomas deficient in all these proteins may be more profoundly dependent on survival and proliferation advantages afforded by activation of the pathway. Nevertheless, PHLPP1 deficiency may result in sustained activation of Akt and render melanoma cells less susceptible to agents that inhibit upstream signals leading to activation of Akt. Therefore, restoration of PHLPP1 may be a useful strategy to improve the therapeutic efficacy of such inhibitors.
MATERIALS AND METHODS
Cell culture, human tissues and reagents
The human melanoma cell lines Mel-CV, ME4405, MM200, Mel-RM, MelRMu, IgR3, Mel-FH and Mel-JD described previously were cultured in DMEM containing 5% fetal calf serum. 55 Human melanocyte lines (HEMa-LP, HEMa-DP and HEMn-LP) were purchased from Banksia Scientific (Bulimba, QLD, Australia) and cultured as previously described. 37 Human fresh melanoma isolates were prepared from fresh surgical specimens according to the published method. 56 TMAs were constructed from formalin-fixed paraffin-embedded melanocytic tumor tissues retrieved from the Department of Tissue Pathology and Diagnostic Oncology at the Royal Prince Alfred Hospital (RPAH) Australia (Supplementary Table S1 ). Studies using human tissues were approved by Human Research Ethics Committees of University of Newcastle and RPAH, Australia. Antibodies against Akt, phospho-Akt (Ser473), ERK, MEK1, phospho-PKCbII (pSer660-PKCbII), PKC, phospho-GSK3b (pGSK3b) and GSK3b were from Cell Signaling Technology (Beverly, MA, USA). The antibody against phospho-ERK (p-ERK) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against p27 and PARP were purchased from BD Biosciences (Bioclone, Marrickville, NSW, Australia). The antibody against Caspase-3 was purchased from Stressgen (Victoria, BC, Canada). Antibodies against PHLPP1 and Sp1 were purchased from Abcam (Cambridge, MA, USA). The antibody against GAPDH was purchased from Ambion (Austin, TX, USA). The antibody against PHLPP2 was purchased from Bethyl Laboratory (Montgomery, TX, USA). 5-Aza-2-Deoxycytidine (5-aza) was purchased from Sigma-Aldrich (Castle Hill, NSW, Australia). LY294002 was purchased from Calbiochem (La Jolla, CA, USA).
Apoptosis
Quantitation of apoptotic cells was carried out by measurement of sub-G1 DNA content using propidium iodide on a flow cytometer as described elsewhere. 57 Anchorage-independent melanocyte growth A total of 5 Â 10 4 melanocytes transduced with the control shRNA, PHLPP1 shRNA1 or PHLPP1 shRNA2 were seeded in 0.3% cell agar layer, which was on top of 0.6% base agar layer in 12-well culture plates. Cells were then incubated for a further 30 days at 37 1C and 5% CO 2 . Cell colony formation was then examined under a light microscope.
Immunoblotting, BrdU proliferation assays and clonogenic assays Immunoblotting, BrdU cell proliferation assays and clonogenic assays were carried out as previously described. 37, 55 Melanoma xenograft mouse model Immunohistochemistry IHC staining and quantitation of immunostained cells were performed as described previously. 58 The PHLPP1 antibody specificity was confirmed by using a blocking peptide that abolished the immunoreactivity in IHC assays.
qPCR analysis of copy number variations Analysis of PHLPP1 copy number variations was carried out as described previously. 59 The specific primers used to examine copy number variation of PHLPP1 were: sense, 5 0 -GCCACATAATCCCCTGGAAC-3 0 , antisense, 5 0 -CCATTGCAGTGGGGCTTC-3 0 . GAPDH was amplified and quantitated as a house keeping control. The primers for GAPDH were: sense, 5 0 -CCTCCCGCTTCGCTCTCT-3 0 , antisense, 5 0 -CCTGGCGACGCAAAAGA-3 0 .
siRNA and shRNA
The siRNA constructs for PHLPP1 and Sp1 were obtained from Shanghai GenePharma Co., Ltd (Shanghai, China). Human PHLPP1 shRNA kit (TG302501) and scramble shRNA kit (TG300130) were purchased from Origene (Karrinyup, WA, Australia).
Plasmid vectors and transfection
The pcDNA3-PHLPP1-HA constructs were generous gifts from Dr Tianyan Gao (Markey Cancer Center, University of Kentucky). 29 The point mutation in AKT3 converting Ser to Asp (AKT/S473D) and in PKC converting Ser to Ala (PKC/S660E) were performed using the QuikChange site-directed mutagenesis kit (Stratagene, Cedar Creek, TX, USA) by following the manufacturer's instructions. Transfection of pCMV6-AC-AKT/S473D and pCMV6-AC-PKC/S660E was carried out as described previously. 37 
Methylation-specific PCR (MS-PCR) analysis
MS-PCR was carried out as previously described. 60 In brief, genomic DNA was treated with sodium bisulfite as described with the Chemicon's CpGenome Fast DNA Modification Kit (S7824, Chemicon, PHLPP1 in melanoma L Dong et al Temecula, CA, USA) and subjected to MS-PCR analysis. The primers specific for methylated DNA were PHLPP1-MF (5 0 -TATGTTTTTTTCGGGATTGTC-3 0 ) and PHLPP1-MR (5 0 -TCAAAATAAACAAACGTAACGC-3 0 ); primers for unmethylated DNA were PHLPP1-UF (5 0 -TATTATGTTTTTTTTGGGATTGTT-3 0 ) and PHLPP1-UR (5 0 -ACTTCAAAATAAACAAACATAACAC-3 0 ). The two sets of primers were designed to amplify the same region in the 5 0 -untranslated region of PHLPP1 gene from À 89 to þ 11.
Luciferase-reporter constructs
The PHLPP1 promoter sequence from 804 bp upstream to 90 bp downstream of the human PHLPP1 gene transcription start site was cloned by genomic PCR using human genomic DNA as a template. Deletions of the promoter were generated by PCR with 5 0 primers and a fixed 3 0 primer. The sequences of these forward primers were: ( À 3/90). The reverse primer was: 5 0 -CCGCTCGAGTGGCGATTCGGAGCA-3 0 . Mutagenesis of the SP1-binding site was performed by PCR using oligonucleotides carrying mutations at the presumed SP1 core recognition sites in combination with the antisense primer ( þ 90). These PHLPP1 promoter fragments were cloned into CpG-free luciferase reporter plasmid pCpGL-Vector. Cells were transiently transfected with the luciferase constructs together with the pRL-TK vector as a control for transfection efficiency. The luciferase activity was measured using the Dual Luciferase Reporter Assay System (Promega, Sydney, NSW, Australia) by Synergy 2 multi-detection microplate reader (BioTek, Winooski, VT, USA).
Chromatin immunoprecipitation assays
ChIP was performed as described previously. 37 The presence of the promoter sequences between À 64 and þ 90 of PHLPP1 was detected using primers: 5 0 -CTGGTTCGCCGGGTTGA-3 0 (forward); 5 0 -TGGCGATTCG GAGCA-3 0 (reverse).
Statistical analysis
Statistical analysis was performed as described previously. 37 
